EUROAPI EUROAPI

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Desvenlafaxine Succinate

    Client Email Product

    Desvenlafaxine Succinate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    46
    US DMFs Filed

    US DMFs Filed

    27
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    14
    Other Suppliers

    Other Suppliers

    28
    API REF. PRICE (USD / KG)
    530

    API Market Place

    9
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    33
    Europe

    Europe

    6
    Canada

    Canada

    15
    Australia

    Australia

    14
    South Africa

    South Africa

    12
    Uploaded Dossiers

    Uploaded Dossiers

    14
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    831.00

    Annual Reports

    206.00

    FDF Market Place

    1
    EXCIPIENTS
    145
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    3

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    16
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    4
    SERVICES
    1
    left grey arrow
    right gray arrow
    • TABLET, EXTENDED RELEASE;ORAL - EQ 100MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 25MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 50MG BASE
    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets

    Details:

    Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Health Canada.


    Lead Product(s): Desvenlafaxine Succinate

    Therapeutic Area: Psychiatry/Psychology Product Name: Desvenlafaxine-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Intellipharmaceutics Corp.

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement August 16, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    pfizer-centreone-m-2023-12-04

    Access Virtual Booth

    Contact Supplier

    View Presentation

    With Virupaksha, you get a quality product with on-time delivery.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search